The DNA analysis company 23andMe will comply with a recent Food and Drug Administration (FDA) directive and halt all health-related genetic testing until further notice. The FDA recently ordered the company to stop selling its DNA test kit, citing concerns over the potential health consequences that could result from false positive or false negative assessments. Although its not the only aspect of 23andMes testing — the company also provides data on ancestry — the health screening is seen as a large reason for its success. Following the FDAs directive, 23andMe swiftly halted all marketing for the health tests, but has now ceased health-related testing entirely. Customers that purchased kits on or before November 21st will receive health-related analysis, but anyone buying a test from November 22nd will only have access to ancestry information and raw test results without analysis.